Ricky Lakhani, Director of Product Management, PHARMASEAL11.20.19
The ever-growing size, risk and complexity of running clinical trials continues to put great pressure on the clinical research industry to evolve practices and challenge not just traditional processes but technologies too. Furthermore, the cost pressures associated with not just clinical trials but the total cost of drug development as a whole adds weight to the argument that companies in this industry cannot simply continue to operate in the same way if they are to introduce the next generation of medicines that will be required for an ageing population. A recent study in 2018 found that “out of 138 pivotal trials assessing 59 new therapies that received FDA approval between 2015 and 2016, there was a more than 100-fold difference in the costs of clinical trials.”1 That rate of growth in costs is just not sustainable in the longer term.
As a scientific industry, we have always employed processes and procedures that are largely scientific in nature. Processes that have been systematic, logical and using the technologies that have been available to us at the time they were actually developed. However, technology in particular has changed dra
As a scientific industry, we have always employed processes and procedures that are largely scientific in nature. Processes that have been systematic, logical and using the technologies that have been available to us at the time they were actually developed. However, technology in particular has changed dra
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
